Evidence map›Paper›PMID 41000962›Full record

ArticlebioRxiv : the preprint server for biology2025

Pancreatic tumor microenvironment reprogramming via alloantigenexpressing virotherapy elicits tumor rejection and improves immunotherapy response.

Mulu Z Tesfay, Aleksandra Cios, Zetao Cheng, Khandoker U Ferdous, Randal S Shelton, Bahaa Mustafa, Natalie M Elliott, Elizabeth A Raupach, Camila C Simoes, Isabelle R Miousse and 14 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Mulu Z TesfayDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Aleksandra CiosDepartment of Pharmacology and Physiology, University of Maryland School of Medicine, 685 W. Baltimore St., Baltimore, MD, 21201, USA.
Zetao ChengDepartment of Pharmacology and Physiology, University of Maryland School of Medicine, 685 W. Baltimore St., Baltimore, MD, 21201, USA.ORCID 0009-0003-9420-197X
Khandoker U FerdousDepartment of Pharmacology and Physiology, University of Maryland School of Medicine, 685 W. Baltimore St., Baltimore, MD, 21201, USA.
Randal S SheltonDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Bahaa MustafaDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Natalie M ElliottDepartment of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Elizabeth A RaupachDepartment of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Camila C SimoesDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Isabelle R MiousseDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0001-6543-3219
Alicja UrbaniakDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Michael A BauerDepartment of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Eric R SiegelDepartment of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Steven R PostDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Jean C ChamcheuDepartment of Pathological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Rang GovindarajanMedical Oncology Division, Internal Medicine Department, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Valery Z GrdzelishviliDepartment of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina, 28223, USA.
Martin J CannonDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Martin E Fernandez-ZapicoSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, MN, 55905, USA.
Alexei G BasnakianDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Chiswili Y ChabuDivision of Biological Sciences, University of Missouri, Columbia, MO, USA.
Omeed MoavenDivision of Surgical Oncology, Department of Surgery, Louisiana State University, Health Science Center, New Orleans, LA 70112, USA.
Mitesh J BoradDepartment of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Bolni M NagaloDepartment of Pharmacology and Physiology, University of Maryland School of Medicine, 685 W. Baltimore St., Baltimore, MD, 21201, USA.

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
Novel Strategies to Enhance Drug Delivery and Tumor Immunogenicity in Pancreatic CancerDP2CA301099 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI NAGALO, BOLNI MARIUS · 2024 to 2024
$1.4M
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular CarcinomaK01CA234324 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI NAGALO, BOLNI MARIUS · 2018 to 2022
$667k
BLRD VA I01 BX002425BLRD VA IK6 BX006184NCI NIH HHS DP2 CA301099NCI NIH HHS K01 CA234324NCI NIH HHS P30 CA134274
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC), the most common malignant type of pancreatic cancer, is characterized by a dense desmoplastic stroma, low neoantigen burden, and a highly immunosuppressive tumor microenvironment (TME), which severely limit cytotoxic T-cell infiltration and the efficacy of immune therapies. Here, we present a novel strategy harnessing acute transplant rejection mechanisms by employing a recombinant oncolytic rVMG vector engineered to express the murine H-2Kk MHC class I alloantigen (rVMG-H-2Kk), thereby inducing tumor-specific antigenic mismatch responses.

Indexed as

alloantigenimmune checkpoint blockadeoncolytic virotherapyPancreatic cancertumor rejection

Identifiers

PMID41000962
PMCPMC12458374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.